BiotechTube
Home/Pipeline/GAGome for MCED

GAGome for MCED

Multi-Cancer Early Detection

Clinical ValidationActive

Key Facts

Indication
Multi-Cancer Early Detection
Phase
Clinical Validation
Status
Active
Company
Elypta

About Elypta

Elypta is an innovative diagnostics company developing a novel, metabolism-focused liquid biopsy platform centered on the GAGome. Its core technology uses mass spectrometry to quantify glycosaminoglycans in biofluids, with applications in multi-cancer early detection, recurrence monitoring for renal cell carcinoma, and risk stratification. The company is in the clinical validation and study phase, actively publishing data and engaging in large-scale European projects like PREDI-LYNCH, positioning itself in the high-growth liquid biopsy market.

View full company profile

Therapeutic Areas

Oncology

Other Multi-Cancer Early Detection Drugs

DrugCompanyPhase
ALMANAC StudyGuardant HealthResearch
Ausel Cancer TestAusel Cancer InnovationPre-clinical
Rivela MCED TestEXOSOMICSPre-clinical
CancerGuard™Exact SciencesPivotal Studies
PATHFINDER 2GRAILInterventional Study
REACH/Galleri-Medicare StudyGRAILProspective Cohort Study
REFLECTION StudyGRAILObservational Study
SUMMIT StudyGRAILObservational Cohort Study
PATHFINDER StudyGRAILInterventional Study
MCED TestMainz BiomedResearch Collaboration